Glutathione s-transferase polymorphisms (GSTM1, GSTP1 and GSTT1) and the risk of acute leukaemia: A systematic review and meta-analysis
Introduction
Acute leukaemia, including acute lymphoblastic leukaemia (ALL) and acute myeloid leukaemia (AML), is a frequent malignancy affecting both children and adults. Despite much investigation, the causes are not yet fully understood. Like many other cancers, acute leukaemia is considered to be a complex disease, which is determined by a combination of genetic and environmental factors [1], [2]. There is increasing evidence that predisposition to acute leukaemia is associated with exposure to chemicals such as benzene and chemotherapeutic agents [3], [4]. The enzymes involved in the metabolism of these carcinogens have thus received a reasonable level of attention.
Glutathione s-transferase (GST) M1, P1 and T1 are phase II enzymes that are involved in conjugation and detoxification of a wide range of xenobiotics, including environmental carcinogens and chemotherapeutic agents. GST polymorphisms have thus been considered as possible risk factors of acute leukaemia. Polymorphisms of GSTM1, GSTP1, and GSTT1 exist in all populations. The GSTM1*0 (GSTM1 null) and GSTT1*0 (GSTT1 null) alleles represent deletions of GSTM1 and GSTT1 genes and result in a loss of enzymatic activity [5]. An increased frequency of GSTM1 and GSTT1 null genotypes has been associated with a number of human malignancies [6], [7]. The 1578 A > G transition in GSTP1 gives rise to the Ile105Val polymorphism, which confers reduced enzyme activity [8].
GST polymorphisms (GSTM1, GSTP1 and GSTT1) were first reported as risk factors for acute leukaemia in 1997 [9], [10]. Since then, a number of studies have confirmed or refuted an association between GST polymorphisms and the risk of acute leukaemia [2], [4], [11], [12], [13], [14], [15], [16], [17], [18], [19], [20], [21], [22], [23], [24], [25], [26], [27], [28]. These disparate findings may be due to insufficient power in some studies, differences between cancer types, type of study populations and study design. To investigate the effect of GST polymorphisms and the risk of acute leukaemia, we performed a systematic review and meta-analysis of all the available published case–control studies from January 1997 to July 2004.
Section snippets
Identification of studies
Studies published between January 1997 and July 2004 with information on GSTM1, GSTP1 or GSTT1 status and the risk of acute leukaemia were identified using two electronic databases: MEDLINE (National Library of Medicine, Washington, DC, USA) and EMBASE (Elsevier Science, New York, USA), using the search terms ‘GSTM1’ or ‘GSTP1’ or ‘GSTT1’ and ‘acute leukaemia’. Additional articles were also checked using the references cited in these publications. Articles selected for analysis were studies
Results
We identified 30 eligible studies, including nearly 12,000 subjects in relation to GST polymorphisms, which are summarised in Table 1, Table 2, Table 3. Thirteen studies were carried out in European countries, 14 in American countries and 3 in Asian countries. Hospital-based controls were used in 7 studies (Table 1). The numbers in the case–control studies varied considerably (range 45–1436 individuals). The frequencies of genotypes varied in the control participants: the frequency of GSTM1
Discussion
GST polymorphisms (GSTM1, GSTP1 and GSTT1) have been evaluated as risk factors for cancers in a number of studies. Molecular epidemiological studies indicate that individuals lacking the genes GSTM1 and GSTT1 are more likely to develop cancer than those having these genes [5]. Based upon this meta-analysis of 30 case–control studies, GSTM1 and GSTT1, but not GSTP1 polymorphisms, appear to be associated with a modest increase in the risk of acute lymphoblastic leukaemia (AML). It is conceivable
Conflict of interest statement
None declared.
Acknowledgements
We thank the anonymous reviewers for their valuable comments. We also thank Andrea Mann and Beth Ireland for proof-reading the manuscript.
References (40)
- et al.
Higher frequency of glutathione s-transferase deletions in black childhood with acute lymphoblastic leukaemia
Blood
(1997) - et al.
Glutathione S-transferase theta 1 (GSTT1) gene defect in myelodysplasia and acute myeloid leukaemia
Lancet
(1997) - et al.
Susceptibility to childhood acute lymophoblastiv leukaemia: influence of CYP1A1, CYP2D6, GSTM1, and GSTT1 genetic polymorphisms
Blood
(1999) - et al.
Genotype of glutathione s-transferase and other genetic configurations in myelodysplasia
Leukemia Res
(1999) - et al.
The glutathione s-transferase mu polymorphism and susceptibility to acute lymphocytic leukaemia
Cancer Lett
(2000) - et al.
Increased risk for therapy-associated hematologic malignancies in patients with carcinoma of the breast and combined homozygous gene deletions of glutathione transferase M1 and T1
Leukemia Res
(2002) - et al.
Glutathione s-transferase genotypes, genetic susceptibility, and outcome of therapy in childhood acute lymphoblastic leukaemia
Blood
(2002) - et al.
CYP1A1*2B(Val) allele is overrepresented in a subgroup of acute myeloid leukaemia patients with poor-risk karyotype associated with NRAS mutation, but not associated with FLT3 internal tandem duplication
Blood
(2003) - et al.
Relationship between glutathione S-transferase M1,T1,P1 polymorphisms and chronic lymphocytic leukaemia
Blood
(2002) - et al.
Meta-analysis in clinical trials
Controlled Clin Trials
(1986)
Childhood acute lymphoblastic leukemia: genetic determinants of susceptibility and disease outcome
Rev Environ Health
Increased risk for acute myeloid leukaemia individuals with glutathione s-transferase mu 1 (GSTM1) and theta 1 (GSTT1) gene defects
Eur J Haematol
Leukemia risk associated with low-level benzene exposure
Epidemiology
Polymorphism in glutathione s-transferase P1 is associated with susceptibility to chemotherapy-induced leukaemia
PNAS
Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility
Cancer Epidemiol Biomarkers Prev
Glutathione S-transferase M1 status and lung cancer risk: a meta-analysis
Cancer Epidemiol Biomarkers Prev
Glutathione S-transferase μ1 (GSTM1) status and bladder cancer risk: a meta-analysis
Mutagenesis
Molecular cloning, characterization, and expression in Escherichia coli of full-length cDNAs of three human glutathione S-transferase Pi gene variants. Evidence for differential catalytic activity of the encoded proteins
J Biol Chem
Genetic polymorphism of CYP2D6, GSTM1 and NAT2 and susceptibility to haematological neoplasias
Carcinogenesis
Glutathione s-transferase thea 1 gene deletion and risk of acute myeloid leukaemia
Cancer Epidemiol Biomarkers Prev
Cited by (143)
Impact of CYP1A1, GSTP1 and XRCC1 genes polymorphisms on toxicity and response to chemotherapy in childhood acute lymphoblastic leukemia
2017, Journal of the Egyptian National Cancer InstituteImpact of GSTT1 and GSTM1 Polymorphisms in the Susceptibility to Philadelphia Negative Chronic Myeloid Leukaemia
2023, Current Cancer Drug Targets